Josu de la Fuente

About

Josu de la Fuente completed his general training in paediatrics in different hospitals in London and following membership of the Royal College of Paediatrics and Child Health, he trained in haematology at Imperial College and Great Ormond Street Hospital achieving membership of the Royal College of Pathologists. During this time he developed an interest in red cell disorders, bone marrow failure and transplantation. After a period of research in human developmental haemopoiesis as an MRC Clinical Research Fellow leading to a PhD, he was appointed to lead the paediatric BMT programme at Imperial College Healthcare, which specialises in transplantation for haemoglobinopathies and bone marrow failure, and has been innovative in the use of alternative donors. He has also developed a unique clinical and research programme for Diamond Blackfan anaemia patients and is part of the iBFM Study Group steering committee for chronic myeloid leukaemia. He is currently the clinical lead for paediatric specialities at Imperial College Healthcare NHS Trust and is a member and haematology lead in the Paediatric Medicine Clinical Reference Group of NHS England.

Employment

• Imperial College Healthcare NHS Trust Consultant Paediatric Haematologist and Director Blood and Marrow Transplant Programme
  2006 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (28)

• Conditioning regimen for hematopoietic cell transplant in transfusion dependent thalassemia: Recommendations from the EBMT practice harmonisation and guidelines committee
  Mohammed Essa, Mattia Algeri, Mohsen Alzahrani

  +13 more

  • Françoise Bernaudin
  • Victoria Bordon
  • Sonali Choudhury
  • Josu de la Fuente
  • Fabio Giglio
  • +8 more
  Bone Marrow Transplantation 2026 DOI: 10.1038/s41409-026-02977-z
  +Save
• Update of the decision-making algorithm on selecting transfusion-dependent β-thalassemic patients for gene therapy approaches: joint consensus report on behalf of EHA-specialized working group and EBMT hemoglobinopathies working party
  Bone Marrow Transplantation 2026 DOI: 10.1038/s41409-026-02947-5
  +Save
• Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease
  Haydar Frangoul, Josu de la Fuente, Yogi Raj Chopra

  +19 more

  • Roland Meisel
  • Persis Jal Amrolia
  • Mattia Algeri
  • Akshay Sharma
  • Maria Domenica Cappellini
  • +14 more
  New England Journal of Medicine 2026 DOI: 10.1056/NEJMoa2603387
  +Save
• Excellent outcomes using a novel reduced intensity conditioning with thiotepa and post-transplant cyclophosphamide for HLA-matched related donor transplant in adolescents and adults with sickle cell disease
  Bone Marrow Transplantation 2026 DOI: 10.1038/s41409-026-02876-3
  +Save
• Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel
  Josu de la Fuente, Haydar Frangoul, Peter Lang +20 more
  Blood Advances 2025 DOI: 10.1182/bloodadvances.2025016702
  +Save
• Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT
  Bone Marrow Transplantation 2024 DOI: 10.1038/s41409-024-02336-w
  +Save
• An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease
  Blood 2024 DOI: 10.1182/blood.2023023301
  +Save
• Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT
  Bone Marrow Transplantation 2024 DOI: 10.1038/s41409-024-02251-0
  +Save
• Outbreak of non-tuberculous mycobacteria in a paediatric bone marrow transplant unit associated with water contamination of needle-free connectors and literature review
  Bone Marrow Transplantation 2021 DOI: 10.1038/s41409-021-01239-4
  +Save
• The role of HLA matching in unrelated donor hematopoietic stem cell transplantation for sickle cell disease in Europe
  Bone Marrow Transplantation 2020 DOI: 10.1038/s41409-020-0847-z
  +Save
• Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID‐19 pandemic
  British Journal of Haematology 2020 DOI: 10.1111/bjh.16687
  +Save
• Single-cell analysis of bone marrow–derived CD34+ cells from children with sickle cell disease and thalassemia
  Blood 2019 DOI: 10.1182/blood.2019002301
  +Save
• Sickle cell disease: the price of cure
  Blood 2016 DOI: 10.1182/blood-2016-10-740969
  +Save
• Nuclease-stimulated homologous recombination at the human β-globin gene
  J Gene Med 2014 DOI: 10.1002/jgm.2751
  +Save
• Target enrichment and high-throughput sequencing of 80 ribosomal protein genes to identify mutations associated with Diamond-Blackfan anaemia
  Br J Haematol 2013 DOI: 10.1111/bjh.12397
  +Save
• Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria.
  2013 DOI: 10.1182/blood-2012-11-469353
  +Save
• Disruption of AP3B1 by a chromosome 5 inversion: a new disease mechanism in Hermansky-Pudlak syndrome type 2
  BMC Medical Genetics 2013 DOI: 10.1186/1471-2350-14-42
  +Save
• Exome sequencing identifies MPL as a causative gene in familial aplastic anemia.
  2012 DOI: 10.3324/haematol.2011.052787
  +Save
• Ineffective hemopoietic in beta thalassemia major visualised
  Am. J. Hematol. 2011 DOI: 10.1002/ajh.21953
  +Save
• Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia.
  2011 DOI: 10.3324/haematol.2010.027839
  +Save